List of Excipients in Branded Drug QUINIDINE SULFATE

Generic Drugs Containing QUINIDINE SULFATE

Company	Ingredient	NDC	Excipient
Eon Labs Inc	quinidine sulfate	0185-4346	CELLULOSE, MICROCRYSTALLINE
Eon Labs Inc	quinidine sulfate	0185-4346	STARCH, CORN
Eon Labs Inc	quinidine sulfate	0185-4346	SUCROSE
Eon Labs Inc	quinidine sulfate	0185-4346	ZINC STEARATE

What are the Most Frequently-Used Excipients in QUINIDINE SULFATE?

# Of NDCs	Excipient
1	CALCIUM STEARATE
3	CELLULOSE, MICROCRYSTALLINE
1	SODIUM STARCH GLYCOLATE TYPE A POTATO
3	STARCH, CORN

Quinidine Sulfate Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Quinidine sulfate is a mature, narrow-therapeutic-index antiarrhythmic with limited standalone commercial scale. The strongest excipient opportunities are not basic tablet manufacture, but differentiated oral delivery: lower-dose precision, improved gastrointestinal tolerability, taste masking, modified release, pediatric dosing, and stable global supply. Generic competition limits pricing power, while formulation and manufacturing patents can still support niche products.

What is the regulatory and commercial status of quinidine sulfate?

Quinidine sulfate is the sulfate salt of quinidine, a Class IA antiarrhythmic used for selected ventricular or supraventricular arrhythmias. Its clinical use has declined because of proarrhythmic risk, QT prolongation, drug interactions, and the availability of alternative therapies. The FDA label warns about torsades de pointes, syncope, thrombocytopenia, cinchonism, and dose-related toxicity [1].

Quinidine sulfate is marketed primarily as an immediate-release oral tablet. Commercial products have historically included 200 mg and 300 mg strengths, with product availability varying by manufacturer and market. The product is generally supplied through generic or specialty channels rather than mass-market primary care.

Attribute	Quinidine sulfate
Active ingredient	Quinidine sulfate
Drug class	Class IA antiarrhythmic
Primary dosage form	Immediate-release oral tablet
Common strengths	200 mg and 300 mg tablets in U.S. labeling
Therapeutic risk	Narrow therapeutic index; QT prolongation and proarrhythmia
FDA pathway	Abbreviated New Drug Application for generic products
Biosimilar relevance	None; quinidine sulfate is a small molecule
Orange Book relevance	Product-specific approved drug listings and patents, if applicable
Commercial profile	Mature, low-volume, specialty and hospital-oriented

The primary commercial constraint is demand, not active pharmaceutical ingredient availability. A successful new product must create value through dosing accuracy, tolerability, supply reliability, or a clinically meaningful delivery advantage.

What excipients are used in quinidine sulfate tablets?

Immediate-release quinidine sulfate tablets generally use conventional solid-dose excipients. Public product labels identify combinations of diluents, binders, disintegrants, lubricants, glidants, and coating materials. Exact composition varies by manufacturer and strength [2].

Typical excipient functions include:

Excipient class	Typical examples	Role in quinidine sulfate tablets
Diluent	Microcrystalline cellulose, lactose, starch	Controls tablet size and content uniformity
Binder	Povidone, pregelatinized starch	Provides granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Promotes rapid tablet breakup
Lubricant	Magnesium stearate, stearic acid	Reduces compression and ejection friction
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Improves appearance, handling, identification, and swallowability
Sweetener or flavor	Product-dependent	Relevant to chewable, liquid, or orally disintegrating formats

Formulation selection requires tighter control than for many standard generics. Excessive hydrophobic lubricant, high polymer loading, or over-compression can delay dissolution. Because quinidine has a narrow safety margin, changes in dissolution or bioavailability may create clinical risk even when the product meets routine assay specifications.

How should an excipient strategy address quinidine sulfate’s narrow therapeutic index?

The formulation target should be reproducible exposure rather than maximum dissolution speed. Three controls are central.

1. Control dissolution across manufacturing scale

The formulation should maintain similar release across:

• Compression-force changes
• Granule-size variation
• Tablet hardness
• Storage humidity
• Different tablet batches
• Manufacturing-site transfers

A robust immediate-release formulation should use a moderate disintegrant level and avoid unnecessary hydrophobic coating or lubricant concentration. Comparative dissolution should be performed across multiple pH conditions, including acidic media and intestinal pH conditions.

2. Minimize excipient-driven pharmacokinetic variability

For a narrow-therapeutic-index drug, excipient changes can trigger regulatory scrutiny. Sponsors should avoid unnecessary switches among:

• High-viscosity cellulose polymers
• Large quantities of surfactants
• pH-modifying agents
• Strong complexing agents
• Excipients with known gastrointestinal permeability effects

The formulation should be designed around a narrow critical quality attribute range for assay, content uniformity, dissolution, degradation products, and tablet disintegration.

3. Manage gastrointestinal tolerability

Quinidine can cause gastrointestinal adverse effects, including nausea, vomiting, diarrhea, and abdominal discomfort [1]. Excipients cannot eliminate quinidine’s intrinsic toxicity, but they can support a better product profile by improving:

• Swallowability
• Tablet surface smoothness
• Dose uniformity
• Controlled release, if clinically justified
• Reduced tablet count
• Palatability for liquid or pediatric formats

A modified-release product could reduce peak-related intolerance, but it would require clinical bridging and a strong justification because delayed or prolonged quinidine exposure could increase arrhythmia risk.

What formulations are protected or commercially attractive for quinidine sulfate?

Immediate-release tablets

Immediate-release tablets are the lowest-risk regulatory route and the most exposed to generic competition. Commercial opportunities include:

• Scored tablets for dose titration
• Smaller tablets for patients with swallowing difficulties
• Color-coded strengths to reduce medication errors
• High content-uniformity products for low-dose regimens
• Packaging optimized for specialty pharmacy distribution

The main barriers are bioequivalence, manufacturing economics, and limited market size.

Extended-release tablets or capsules

An extended-release product could reduce dosing frequency and potentially moderate peak plasma exposure. The formulation could use:

• Hydrophilic matrix polymers
• Insoluble matrix systems
• Multiparticulate pellets
• Coated beads in capsules
• Osmotic or membrane-controlled systems

This segment has higher commercial value but also greater technical and regulatory risk. The sponsor would need to establish consistent release under fed and fasted conditions, demonstrate dose proportionality where applicable, and address alcohol-induced dose dumping if a matrix or coated-particle system is used.

Oral liquid

An oral solution or suspension could support:

• Pediatric cardiology
• Patients unable to swallow tablets
• Hospital dose adjustment
• Extemporaneous-free dispensing
• More precise low-dose titration

The principal excipient issues are taste, chemical stability, microbial preservation, pH control, and adsorption to container surfaces. Quinidine’s bitter taste makes flavoring alone unlikely to provide adequate masking. A combination of sweetener, flavor, viscosity modifier, and taste-masking technology may be required.

Potential excipient components include buffered aqueous vehicles, glycerol or sorbitol, suspending agents, chelators, preservatives, and pH adjusters. Each component must be evaluated for compatibility with quinidine sulfate, especially under accelerated stability conditions.

Orally disintegrating or buccal formats

Orally disintegrating tablets could address swallowing difficulty, but the benefit is uncertain because quinidine is bitter and dosing may need to be titrated carefully. Taste-masking coatings, ion-exchange resins, complexation, or multilayer compression could improve acceptability.

A buccal or sublingual product is less attractive. It could create rapid absorption and peak concentrations that increase proarrhythmic risk unless the delivery rate is tightly controlled.

What manufacturing and excipient barriers affect commercial entry?

Quinidine sulfate excipient strategy is constrained by four manufacturing risks.

Content uniformity

Low-dose products require reliable API distribution. Direct compression may be unsuitable if quinidine sulfate has poor flow or segregation behavior. Wet granulation or dry granulation may provide better uniformity, but both introduce scale-up variables.

Moisture sensitivity

Moisture can affect tablet hardness, disintegration, dissolution, and degradation. Packaging may require high-barrier blister systems or tightly sealed bottles with desiccant protection.

Salt and pH behavior

Quinidine sulfate’s solubility and stability can change with pH and ionic conditions. Buffer selection is especially important in liquid and modified-release products.

Supply continuity

A differentiated product can gain commercial value if it reduces shortages or improves manufacturing reliability. Dual sourcing of API, excipients, coating materials, and packaging is important for a low-volume product because a single-site disruption can materially affect market supply.

How many patents cover quinidine sulfate products?

Standalone quinidine sulfate is an old small-molecule product with no meaningful remaining composition-of-matter exclusivity in the United States. Commercial protection depends on formulation, delivery system, manufacturing process, or use claims rather than the active ingredient itself.

Protection category	Commercial relevance
Quinidine sulfate composition of matter	Expired or commercially exhausted
Immediate-release tablet formulation	Usually weak unless a specific formulation is claimed
Extended-release delivery	Potentially protectable through polymer, pellet, coating, or release-profile claims
Oral liquid	Potential protection for stability, taste masking, or preservative systems
Manufacturing process	Possible protection where the process improves purity, uniformity, or yield
Method of use	Limited for established antiarrhythmic uses; stronger only for a newly supported indication
Combination product	Separate analysis required, particularly for dextromethorphan/quinidine products

Patent durability depends on claim scope and filing date. A routine excipient substitution is unlikely to create a strong patent position. A platform combining a specific quinidine particle size, coating architecture, dissolution profile, and clinical dosing schedule has greater potential.

What is the Orange Book and FDA status of quinidine sulfate?

Quinidine sulfate products approved through ANDAs are subject to generic-drug requirements, including pharmaceutical equivalence, bioequivalence, manufacturing compliance, and labeling conformity. FDA Orange Book records should be reviewed for the specific product, dosage form, strength, reference-listed drug, and any listed patents or exclusivity [3].

For a mature standalone quinidine sulfate product, the expected regulatory pathway is an ANDA rather than a 505(b)(2) application. A 505(b)(2) strategy may be more appropriate for:

• A new extended-release dosage form
• A novel oral liquid
• A new administration route
• A clinically differentiated formulation
• A new dosing regimen supported by additional clinical evidence

A product using quinidine sulfate in combination with dextromethorphan is a separate regulatory and patent category. Nuedexta is approved for pseudobulbar affect and contains dextromethorphan hydrobromide and quinidine sulfate. Its regulatory and Orange Book status should not be treated as interchangeable with standalone quinidine sulfate [4].

Are there Paragraph IV challenges or generic litigation risks?

Standalone quinidine sulfate has limited Paragraph IV litigation value because the active ingredient and conventional tablet technology are mature. A Paragraph IV challenge would be more relevant against a later innovative product with:

• An extended-release profile
• A proprietary multiparticulate system
• A novel liquid formulation
• A patented taste-masking system
• A combination product
• A newly approved method of use

Generic launch risk for conventional immediate-release tablets is high once an ANDA is approved, assuming adequate supply and commercial demand. The main barriers are bioequivalence execution, manufacturing economics, and market size rather than patent enforcement.

For combination products containing quinidine sulfate, litigation risk can be materially higher because formulation and method-of-use patents may remain relevant. The commercial analysis must separate the quinidine sulfate molecule from the protected combination, indication, and dosage regimen.

Which companies are positioned to commercialize quinidine sulfate?

The market is most suitable for:

• Generic manufacturers with low-volume specialty portfolios
• Hospital-focused suppliers
• Contract manufacturers with flexible tablet and liquid capacity
• Specialty pharmacies
• Firms with pediatric formulation capabilities
• Companies seeking shortage-resistant products

Large primary-care generic manufacturers may find the market too small unless the product is bundled with other cardiovascular or hospital medicines. A specialty manufacturer can earn better returns through supply reliability, a differentiated dosage form, or a niche indication.

Licensing opportunities are more likely to involve formulation technology than the quinidine sulfate molecule. Relevant assets could include taste-masking platforms, multiparticulate coating systems, pediatric liquid vehicles, and high-barrier packaging systems.

How does quinidine sulfate compare with the dextromethorphan/quinidine combination?

Issue	Standalone quinidine sulfate	Dextromethorphan/quinidine combination
Primary use	Selected arrhythmias	Pseudobulbar affect
Commercial demand	Limited and specialty-oriented	More commercially established
Patent risk	Generally low for conventional tablets	Higher due to combination and method-of-use protection
Regulatory pathway	ANDA for generic tablet	NDA or regulated generic pathway for the specific combination
Excipient opportunity	Dose precision, release control, liquid, pediatric use	Combination stability, capsule performance, dose uniformity
Competitive risk	High generic substitution	Greater brand, patent, and indication complexity
Biosimilar relevance	None	None

The combination product has greater commercial potential but also stronger regulatory and patent barriers. Standalone quinidine sulfate is more accessible for generic development but offers less pricing power.

What generic launch scenarios exist for quinidine sulfate?

Base-case scenario

A conventional immediate-release tablet enters through an ANDA and competes on supply, price, and wholesaler coverage. Margins remain limited because the product is mature and interchangeable.

Differentiated specialty scenario

A sponsor launches a scored, high-uniformity tablet with reliable supply and specialty-pharmacy distribution. The product gains share without requiring a new clinical indication.

Pediatric formulation scenario

An oral solution or suspension targets pediatric cardiology and hospital use. The opportunity depends on taste masking, stability, preservative performance, and clinician adoption.

505(b)(2) reformulation scenario

An extended-release dosage form seeks reduced dosing frequency or improved tolerability. This offers the largest potential value but requires the highest development investment and clinical evidence.

Key Takeaways

• Quinidine sulfate is a mature, narrow-therapeutic-index small molecule with limited standalone market growth.
• Conventional immediate-release tablets have low patent barriers and high generic substitution risk.
• Excipient selection should prioritize dissolution control, content uniformity, moisture protection, and gastrointestinal tolerability.
• Oral liquids, pediatric products, and extended-release systems offer the clearest commercial differentiation.
• A modified-release product may support stronger formulation patents but requires substantial pharmacokinetic and clinical validation.
• Quinidine sulfate should be analyzed separately from the protected dextromethorphan/quinidine combination.
• The best commercial fit is a specialty or hospital supplier with reliable low-volume manufacturing and differentiated delivery technology.

FAQs About Quinidine Sulfate Excipients and Commercialization

Can quinidine sulfate be formulated as an oral suspension?

Yes. An oral suspension is technically feasible, but taste masking, chemical stability, sedimentation control, preservative efficacy, and dose uniformity are critical development issues.

What excipient is most important for quinidine sulfate tablet performance?

No single excipient controls performance. The most important system-level variables are the disintegrant, lubricant level, binder, compression force, and moisture-control strategy because they jointly determine dissolution and content uniformity.

Does quinidine sulfate have biosimilar competition?

No. Quinidine sulfate is a small molecule and is subject to generic-drug competition rather than the biosimilar pathway.

Can an extended-release quinidine sulfate product receive new patent protection?

Yes. New claims may cover a specific release mechanism, multiparticulate architecture, polymer combination, dissolution profile, stability profile, or manufacturing process. The claims must provide more than a routine excipient substitution.

Is quinidine sulfate commercially attractive for a large generic manufacturer?

Usually not as a standalone volume product. Its stronger fit is with specialty manufacturers, hospital suppliers, pediatric formulation companies, and firms able to monetize supply reliability or differentiated dosage forms.

References

1. U.S. Food and Drug Administration. (n.d.). Quinidine sulfate tablets: Prescribing information. DailyMed.
2. National Library of Medicine. (n.d.). Quinidine sulfate tablet product labeling and inactive ingredients. DailyMed.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (n.d.). Nuedexta prescribing information. DailyMed.